CLASS II Drug recall · Reported 17 Aug 2022 · FDA Enforcement Report

Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg recalled

Glenmark Pharmaceuticals Inc., U is recalling Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg, distributed nationwide in the US. The recall was initiated on 29 Jun 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLots 17210929 & 17210930, Exp Date 05/2023; Lot 17211203, Exp Date 06/2023 & Lots 17211643, 17211646 & 17211649, Exp Date 08/2023
NDC68462-840, 68462-841, 68462-842
UPC0368462842133, 0368462841136, 0368462840139

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1306-2022
FDA event ID
90541
Recalling firm
Glenmark Pharmaceuticals Inc., U, Mahwah, NJ
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Classification
Class II
Status
Terminated
Recall initiated
29 Jun 2022
FDA classified
5 Aug 2022
Reported
17 Aug 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

29 Jun 2022Recall initiated by company
5 Aug 2022Classified by FDA+37 days
17 Aug 2022Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Product as listed by the FDA

Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg, 30 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot no 2, Phase-2, Pharma Zone, SEZ Pithampur, District Dhar, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc,m USA, Mahwah, NJ 07430, NDC 68462-841-13.

Where it was distributed

nationwide

Nationwide

Questions about this recall

Is Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg recalled?

Yes. Glenmark Pharmaceuticals Inc., U recalled Telmisartan and Hydrochlorothiazide Tablets USP, 80 mg/12.5 mg on 29 Jun 2022. The recall is Class II and its status is Terminated. Recall number D-1306-2022.

Why was it recalled?

Defective Container: Recall of these batches has been initiated due to complaints of difficult to open blister and tablet breaks while opening the blister .

Which lots are affected?

Lots 17210929 & 17210930, Exp Date 05/2023; Lot 17211203, Exp Date 06/2023 & Lots 17211643, 17211646 & 17211649, Exp Date 08/2023

Where was it sold?

nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., U

All 141

Other Telmisartan recalls

All 6